麻豆传媒

Charles Bankhead

Charles Bankhead

Authors >

Charles Bankhead

Charles Bankhead is senior editor for oncology and also covers urology, dermatology, and ophthalmology. His career spans more than 30 years, including a decade with Medical World News, a leading medical trade magazine of its time. He had a long and successful freelance career before joining 麻豆传媒 in 2007. Charles graduated with honors from Texas Tech University, receiving a BA in journalism, and completed a master's degree in mass communication, with specialization in health communication, also at Texas Tech.

Connect:

email image

Latest from Charles Bankhead

ASCO: Targeted Combo Extends PFS in Ovarian Ca

CHICAGO -- Progression-free survival almost doubled in women with platinum-sensitive relapsed ovarian cancer treated with two targeted drugs instead of one, investigators reported here.

AUA Offers Guidance for Kidney Stones

ORLANDO -- Treatment tailored to individual patient and stone characteristics provides the basis for an American Urological Association clinical guideline on medical management of kidney stones.

Enzyme Tx Durable for Peyronie's

ORLANDO -- Three-fourths of men with moderate to severe Peyronie's disease had meaningful improvement a year after treatment with an enzyme that dissolves scar tissue, investigators reported here.

FDA Warns of Cancer Risk With Laparoscopic Device

WASHINGTON -- Hysterectomy and procedures to remove uterine fibroids should avoid use of laparoscopic power morcellation, according to a safety advisory from the Food and Drug Administration.

Cologuard Cancer Test Aces FDA Panel Review

WASHINGTON -- An FDA advisory committee unanimously affirmed the safety and efficacy of a DNA stool test for colorectal cancer screening.

Anti-PARP Tx Works in Advanced Ovarian Cancer

TAMPA, Fla. -- Advanced ovarian cancer treated with PARP inhibitor maintenance therapy had significant improvement in progression-free survival, extending beyond first progression, investigators reported.

Cancer Ascites Responds to Outpatient Tx

TAMPA, Fla. -- Outpatient treatment of malignant ascites with a monoclonal antibody proved safe and feasible and led to a survival benefit in gynecologic cancer patients who could receive chemotherapy, a small clinical study showed.

OncoBriefs: Myeloma Tx, In Situ Melanoma

Superficial melanoma conferred a risk of recurrent invasive melanoma similar to that of primary invasive melanoma, Australian investigators reported. The study is one of several oncology-related news items summarized in OncoBriefs.

OncoBriefs: Zalutumumab Misses Mark in H&N Cancer

SCOTTSDALE, Ariz. -- Chemoradiation plus the targeted agent zalutumumab failed to improve disease control or survival in patients with squamous cell head and neck cancer, a finding that leads this roundup of news from the Multidisciplinary Head and Neck Cancer Symposium.

Combo Active in Neuroendocrine Cancers

SAN FRANCISCO -- More than 90% of patients with neuroendocrine tumors had objective responses or stable disease when treated with an off-the-shelf chemotherapy doublet, results of a small study showed.

鈥�

108

鈥�